These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36713520)

  • 21. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
    Scheufele F; Friess H
    Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Borderline resectable pancreatic cancer: on the edge of survival.
    Springett GM; Hoffe SE
    Cancer Control; 2008 Oct; 15(4):295-307. PubMed ID: 18813197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer.
    Scheufele F; Hartmann D; Friess H
    Transl Gastroenterol Hepatol; 2019; 4():32. PubMed ID: 31231699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
    van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
    Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.
    Hoffe S; Rao N; Shridhar R
    Semin Radiat Oncol; 2014 Apr; 24(2):113-25. PubMed ID: 24635868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades.
    Taboada AGM; Lominchar PL; Roman LM; García-Alfonso P; Martin AJM; Rodriguez JAB; Pascual JMA
    Ann Hepatobiliary Pancreat Surg; 2021 May; 25(2):179-191. PubMed ID: 34053920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer.
    Lu C; Zhu Y; Kong W; Yang J; Zhu L; Wang L; Tang M; Chen J; Li Q; He J; Li A; Qiu X; Gu Q; Chen D; Meng F; Liu B; Qiu Y; Du J
    Front Oncol; 2022; 12():879661. PubMed ID: 36059628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study.
    Parsonson AO; Connolly E; Lee M; Hruby G; Sandroussi C; Merrett N; Samra J; Mittal A; Tse R; Grimison P
    ANZ J Surg; 2021 Nov; 91(11):2447-2452. PubMed ID: 34427029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.
    Gilbert JW; Wolpin B; Clancy T; Wang J; Mamon H; Shinagare AB; Jagannathan J; Rosenthal M
    Ann Oncol; 2017 Sep; 28(9):2067-2076. PubMed ID: 28407088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.
    Gillen S; Schuster T; Meyer Zum Büschenfelde C; Friess H; Kleeff J
    PLoS Med; 2010 Apr; 7(4):e1000267. PubMed ID: 20422030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.
    White R; Lee C; Anscher M; Gottfried M; Wolff R; Keogan M; Pappas T; Hurwitz H; Tyler D
    Ann Surg Oncol; 1999; 6(1):38-45. PubMed ID: 10030414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.
    Wittel UA; Lubgan D; Ghadimi M; Belyaev O; Uhl W; Bechstein WO; Grützmann R; Hohenberger WM; Schmid A; Jacobasch L; Croner RS; Reinacher-Schick A; Hopt UT; Pirkl A; Oettle H; Fietkau R; Golcher H
    BMC Cancer; 2019 Oct; 19(1):979. PubMed ID: 31640628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX.
    Choi JH; Kim MK; Lee SH; Park JW; Park N; Cho IR; Ryu JK; Kim YT; Jang JY; Kwon W; Kim H; Paik WH
    Front Oncol; 2022; 12():945829. PubMed ID: 36226066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
    JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant treatment of localized pancreatic adenocarcinoma.
    Leal AD; Messersmith WA; Lieu CH
    J Gastrointest Oncol; 2021 Oct; 12(5):2461-2474. PubMed ID: 34790407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiotherapy for Pancreatic Adenocarcinoma: Recent Developments and Advances on the Horizon.
    Salamekh S; Gottumukkala S; Park C; Lin MH; Sanford NN
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):995-1009. PubMed ID: 36154787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant and Adjuvant Therapy in Operable Pancreatic Cancer: Both Honey and Milk (but No Bread?).
    Søreide K
    Oncol Ther; 2021 Jun; 9(1):1-12. PubMed ID: 33439449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.
    Janssen QP; van Dam JL; Bonsing BA; Bos H; Bosscha KP; Coene PPLO; van Eijck CHJ; de Hingh IHJT; Karsten TM; van der Kolk MB; Patijn GA; Liem MSL; van Santvoort HC; Loosveld OJL; de Vos-Geelen J; Zonderhuis BM; Homs MYV; van Tienhoven G; Besselink MG; Wilmink JW; Groot Koerkamp B;
    BMC Cancer; 2021 Mar; 21(1):300. PubMed ID: 33757440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry.
    Stessin AM; Meyer JE; Sherr DL
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1128-33. PubMed ID: 18538501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.